Moderna-Merck mRNA Vaccine Reduces Melanoma Risk by 49% in 5 Years
A personalized mRNA vaccine developed by Moderna and Merck significantly reduced the risk of melanoma recurrence or death by 49 percent over five years, according to clinical trial results published in the Journal of Clinical Oncology. The findings suggest a durable benefit for high-risk patients following surgical tumor removal. Five-Year Outcomes for the mRNA Vaccine … Read more